Related Articles by Review for PMID: 34283418

Year	Number of Results
1995	1
1996	1
1997	1
2006	1
2009	1
2011	2
2012	1
2014	4
2017	2
2020	1
2021	2
2023	2
2024	2
2025	1

1

Roberts AD, Wadhwa R. Roberts AD, et al. 2023 Jun 5. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2023 Jun 5. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 34283418 Free Books & Documents.

2

Challenges in Evaluating Safety and Efficacy in Drug Development for Rare Diseases: A Review for Pharmacists.

Shah KK, Kogut S, Slitt A. Shah KK, et al. J Pharm Pract. 2021 Jun;34(3):472-479. doi: 10.1177/0897190020930972. Epub 2020 Jun 25. J Pharm Pract. 2021. PMID: 32583733 Review.

3

Proposed 'grant-and-access' program with price caps could stimulate development of drugs for very rare diseases.

Valverde AM, Reed SD, Schulman KA. Valverde AM, et al. Health Aff (Millwood). 2012 Nov;31(11):2528-35. doi: 10.1377/hlthaff.2012.0235. Health Aff (Millwood). 2012. PMID: 23129684 Review.

4

Incentivizing Orphan Product Development: United States Food and Drug Administration Orphan Incentive Programs.

Le TT. Le TT. Adv Exp Med Biol. 2017;1031:183-196. doi: 10.1007/978-3-319-67144-4_10. Adv Exp Med Biol. 2017. PMID: 29214572 Review.

5

The economics of orphan drug policy in the US. Can the legislation be improved?

Peabody JW, Ruby A, Cannon P. Peabody JW, et al. Pharmacoeconomics. 1995 Nov;8(5):374-84. doi: 10.2165/00019053-199508050-00002. Pharmacoeconomics. 1995. PMID: 10160072 Review.

6

The US orphan drug programme 1983-1995.

Shulman SR, Manocchia M. Shulman SR, et al. Pharmacoeconomics. 1997 Sep;12(3):312-26. doi: 10.2165/00019053-199712030-00004. Pharmacoeconomics. 1997. PMID: 10170457 Review.

7

World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.

Kontoghiorghe CN, Andreou N, Constantinou K, Kontoghiorghes GJ. Kontoghiorghe CN, et al. World J Methodol. 2014 Sep 26;4(3):163-88. doi: 10.5662/wjm.v4.i3.163. eCollection 2014 Sep 26. World J Methodol. 2014. PMID: 25332915 Free PMC article. Review.

8

The use of the United States FDA programs as a strategy to advance the development of drug products for neglected tropical diseases.

Sachs-Barrable K, Conway J, Gershkovich P, Ibrahim F, Wasan KM. Sachs-Barrable K, et al. Drug Dev Ind Pharm. 2014 Nov;40(11):1429-34. doi: 10.3109/03639045.2014.884132. Epub 2014 Feb 11. Drug Dev Ind Pharm. 2014. PMID: 24512098 Review.

9

Orphan drug policy analysis in China.

Liu M, Lu Y, Li J, Zhang Y, Zhang S, Liu Y. Liu M, et al. Front Pharmacol. 2024 Jun 13;15:1278710. doi: 10.3389/fphar.2024.1278710. eCollection 2024. Front Pharmacol. 2024. PMID: 38939834 Free PMC article. Review.

10

Unapproved drugs in the United States and the Food and Drug Administration.

Nasr A, Lauterio TJ, Davis MW. Nasr A, et al. Adv Ther. 2011 Oct;28(10):842-56. doi: 10.1007/s12325-011-0059-4. Epub 2011 Sep 1. Adv Ther. 2011. PMID: 21894470 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

20 results

Results by year

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Related Articles by Review for PMID: 34283418

20 results

Results by year